With Market Size Valued at $185.4 Million by 2026, it`s a Healthy Outlook for the Global Bulk Paclitaxel Market

BY PR Newswire | ECONOMIC | 07/04/22 03:15 AM EDT

SAN FRANCISCO, July 4, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled?"Bulk Paclitaxel - Global Market Trajectory & Analytics". The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace.

With Market Size Valued at $185.4 Million by 2026, it`s a Healthy Outlook for the Global Bulk Paclitaxel Market

What's New for 2022?

  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to our digital archives and MarketGlass Research Platform
  • Complimentary updates for one year

Edition:?17;?Released:?January 2022
Executive Pool:?1333
Companies:?33 - Players covered include Fresenius Kabi AG; Guilin Huiang Biochemistry Pharmaceutical Co., Ltd.; Hainan Yeshanyuan Pharmaceutical Co., Ltd.; Novasep Holding SAS; Phyton Biotech; Poly Medicure Ltd.; Samyang Biopharmaceuticals Corporation; ScinoPharm Taiwan Ltd.; Teva API, Inc.; Yunnan Hande Bio-tech Co., Ltd./Hande Bio-Source, Inc. (HBS) and Others.
Coverage:?All major geographies and key segments
Segments:?Product (Semi-Synthetic Paclitaxel API, Natural Paclitaxel API); Application (Ovarian Cancer, Breast Cancer, Cervical Cancer, Other Applications)
Geographies:?World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific ; Latin America ; Middle East ; and Africa.

Complimentary Project Preview -?This is an ongoing global program. Preview our research program before you make a purchase decision. We are offering a complimentary access to qualified executives driving strategy, business development, sales & marketing, and product management roles at featured companies. Previews provide deep insider access to business trends; competitive brands; domain expert profiles; and market data templates and much more. You may also build your own bespoke report using our MarketGlass? Platform which offers thousands of data bytes without an obligation to purchase our report.?Preview Registry


Global Bulk Paclitaxel Market to Reach $185.4 Million by 2026
Amid the COVID-19 crisis, the global market for Bulk Paclitaxel estimated at US$98.2 Million, is projected to reach a revised size of US$185.4 Million by 2026, growing at a CAGR of 10.9% over the analysis period. Natural Paclitaxel API, one of the segments analyzed in the report, is projected to record a 10.3% CAGR and reach US$68.8 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Semi-Synthetic Paclitaxel API segment is readjusted to a revised 11.2% CAGR for the next 7-year period.

The U.S. Market is Estimated at $29.6 Million in 2021, While China is Forecast to Reach $38.3 Million by 2026
The Bulk Paclitaxel market in the U.S. is estimated at US$29.6 Million in the year 2021. China, the world`s second largest economy, is forecast to reach a projected market size of US$38.3 Million by the year 2026 trailing a CAGR of 14.3% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.6% and 9.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.6% CAGR.


MarketGlass? Platform
Our MarketGlass? Platform is a free full-stack knowledge center that is custom configurable to today`s busy business executive`s intelligence needs! This influencer driven interactive research platform is at the core of our primary research engagements and draws from unique perspectives of participating executives worldwide. Features include - enterprise-wide peer-to-peer collaborations; research program previews relevant to your company; 3.4 million domain expert profiles; competitive company profiles; interactive research modules; bespoke report generation; monitor market trends; competitive brands; create & publish blogs & podcasts using our primary and secondary content; track domain events worldwide; and much more. Client companies will have complete insider access to the project data stacks. Currently in use by 67,000+ domain experts worldwide.

Our platform is free for qualified executives and is accessible from our website www.StrategyR.com or via our just released mobile application on?iOS?or?Android

About Global Industry Analysts, Inc. & StrategyR?
Global Industry Analysts, Inc., (www.strategyr.com) is a renowned market research publisher the world`s only influencer driven market research company. Proudly serving more than 42,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for over 33 years.

Zak Ali
Director, Corporate Communications
Global Industry Analysts, Inc.
Phone: 1-408-528-9966
Email: ZA@StrategyR.com

Join Our Expert Panel

Connect With Us on LinkedIn

Follow Us on Twitter

Journalists & Media

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/with-market-size-valued-at-185-4-million-by-2026--its-a-healthy-outlook-for-the-global-bulk-paclitaxel-market-301579365.html

SOURCE Global Industry Analysts, Inc.

In general the bond market is volatile, and fixed income securities carry interest rate risk. (As interest rates rise, bond prices usually fall, and vice versa. This effect is usually more pronounced for longer-term securities.) Fixed income securities also carry inflation risk and credit and default risks for both issuers and counterparties. Unlike individual bonds, most bond funds do not have a maturity date, so avoiding losses caused by price volatility by holding them until maturity is not possible.

Lower-quality debt securities generally offer higher yields, but also involve greater risk of default or price changes due to potential changes in the credit quality of the issuer. Any fixed income security sold or redeemed prior to maturity may be subject to loss.

Before investing, consider the funds' investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus or, if available, a summary prospectus containing this information. Read it carefully.